978-P: Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit

Le résumé fourni par la source

Introduction and Objective: To evaluate the accuracy and reproducibility of the Dexcom G7 sensor in a hospital ICU setting in persons with diabetes or stress hyperglycemia in the absence of diabetes. Methods: At a U.S. academic center, 30 adults hospitalized in the ICU with either diabetes (N=12) or stress hyperglycemia without diabetes (n=18) wore 2 Dexcom G7 sensors simultaneously that were blinded for the purpose of the study. CGM glucose values were paired with venous or capillary blood glucose (BG) measurements for accuracy analyses. Reproducibility of the 2 simultaneously worn sensors was assessed. Results: For 1515 CGM-BG pairs, the median relative absolute difference (RAD) was 12%, with 72% of CGM values either within 20% (when BG ≥100 mg/dL) or 20 mg/dL (when BG <100 mg/dL) of the corresponding BG value (Table). Median RAD was consistent across the first 8 days of sensor wear (insufficient data subsequently). Median difference (CGM minus BG) was -6 mg/dL. For 28,926 paired CGM values from 2 simultaneously worn sensors, median RAD was 11%. Conclusion: In the ICU setting, the accuracy and reproducibility of the G7 sensor were very good and close to the accuracy achieved in the outpatient setting. The G7 sensor may be a useful tool for monitoring BG levels in the ICU. Disclosure J.D. Baran: None. C. Spanbauer: None. R. Bais: None. H. Chiang: None. J.H. Chao: Research Support; Dexcom, Inc. D. Khakpour: None. P. Panfil: None. F.J. Pasquel: Consultant; Insulet Corporation. Research Support; Novo Nordisk, Dexcom, Inc., Ideal Medical Technologies, Tandem Diabetes Care, Inc, Insulet Corporation. Consultant; Dexcom, Inc. J. Ullal: None. M.S. Jones: None. C.C. Low Wang: Research Support; Dexcom, Inc., Virta Health Corp. J.B. Buse: Other Relationship; Corcept Therapeutics, Dexcom, Inc., Novo Nordisk. Consultant; Altimmune Inc, Amgen Inc, ApStem, Aqua Medical, AstraZeneca, Boehringer-Ingelheim, CeQur, Eli Lilly and Company, embecta, GentiBio. Other Relationship; Glyscend Therapeutics. Consultant; Insulet Corporation, Medtronic. Other Relationship; Mellitus Health. Consultant; Metsera. Other Relationship; Pendulum Therapeutics, Praetego, Stability Health. Consultant; Tandem Diabetes Care, Inc, TERNS Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S. B. Draznin: None. J. Sibayan: None. C. Kollman: Research Support; Dexcom, Inc., Insulet Corporation, MannKind Corporation, Breakthrough T1D (formerly JDRF), Capillary Biomedical, Inc, Hemsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases, Tandem Diabetes Care, Inc. R.W. Beck: Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Tandem Diabetes Care, Inc, Beta Bionics, Inc, Dexcom, Inc., Bigfoot Biomedical, Inc, Abbott, embecta, Sequel Med Tech, MannKind Corporation. Consultant; Novo Nordisk, Vertex Pharmaceuticals Incorporated, Hagar, Ypsomed AG, Zucara Therapeutics, Abata Therapeutics, Eli Lilly and Company. I.B. Hirsch: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc, MannKind Corporation. Consultant; Abbott, Roche Diabetes Care, Hagar. Funding Dexcom; National Institutes of Diabetes and Digestive and Kidney Disease (P30DK124723 and 2P30DK111024-06); National Center for Advancing Translational Sciences (UM1TR004406 and 3UL1TR002378-05S2)

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.